U.S. flag

An official website of the United States government

Format
Items per page
Sort by
Choose Destination

Links from MedGen

Items: 1 to 100 of 135

VariationLocationGene(s)Protein changeCondition(s)Clinical significance
(Last reviewed)
Review status
1.
GRCh37:
Chr6:32010726
GRCh38:
Chr6:32042949
LOC106780803, TNXBEhlers-Danlos syndrome due to tenascin-X deficiencyLikely pathogenic
(Jun 6, 2023)
criteria provided, single submitter
2.
GRCh37:
Chr6:32037581
GRCh38:
Chr6:32069804
TNXBG1779EEhlers-Danlos syndrome due to tenascin-X deficiencyUncertain significance
(May 7, 2021)
criteria provided, single submitter
3.
TNXBEhlers-Danlos syndrome due to tenascin-X deficiencyUncertain significancecriteria provided, single submitter
4.
GRCh37:
Chr6:32036406
GRCh38:
Chr6:32068629
TNXBT1994IEhlers-Danlos syndrome due to tenascin-X deficiency, Vesicoureteral reflux 8Uncertain significance
(Mar 30, 2021)
criteria provided, single submitter
5.
GRCh37:
Chr6:32036856
GRCh38:
Chr6:32069079
TNXBP1882LVesicoureteral reflux 8, Ehlers-Danlos syndrome due to tenascin-X deficiencynot providedno assertion provided
6.
GRCh37:
Chr6:32049423-32049424
GRCh38:
Chr6:32081646-32081647
TNXBR1255fsVesicoureteral reflux 8, Ehlers-Danlos syndrome due to tenascin-X deficiencyPathogenic/Likely pathogenic
(May 31, 2022)
criteria provided, multiple submitters, no conflicts
7.
GRCh37:
Chr6:32065945
GRCh38:
Chr6:32098168
TNXBS11CEhlers-Danlos syndrome due to tenascin-X deficiencyLikely pathogenic
(Jun 30, 2022)
no assertion criteria provided
8.
GRCh37:
Chr6:32047074
GRCh38:
Chr6:32079297
TNXBE1371KInborn genetic diseasesUncertain significance
(Jul 26, 2022)
criteria provided, single submitter
9.
GRCh37:
Chr6:32046965
GRCh38:
Chr6:32079188
TNXBK1407REhlers-Danlos syndrome due to tenascin-X deficiencyUncertain significance
(Aug 1, 2022)
criteria provided, single submitter
10.
GRCh37:
Chr6:32010281
GRCh38:
Chr6:32042504
LOC106780803, TNXBR4052P, R4054P, R483PEhlers-Danlos syndrome due to tenascin-X deficiencyUncertain significance
(Aug 1, 2022)
criteria provided, single submitter
11.
GRCh37:
Chr6:32063845
GRCh38:
Chr6:32096068
TNXBS595REhlers-Danlos syndrome due to tenascin-X deficiencyUncertain significance
(Apr 12, 2022)
criteria provided, single submitter
12.
GRCh37:
Chr6:32047017
GRCh38:
Chr6:32079240
TNXBL1390VEhlers-Danlos syndrome due to tenascin-X deficiencyUncertain significance
(Feb 21, 2022)
criteria provided, single submitter
13.
GRCh37:
Chr6:32062902-32062910
GRCh38:
Chr6:32095125-32095133
TNXBEhlers-Danlos syndrome due to tenascin-X deficiencyUncertain significance
(Feb 15, 2022)
criteria provided, single submitter
14.
GRCh37:
Chr6:32063824
GRCh38:
Chr6:32096047
TNXBD602EEhlers-Danlos syndrome due to tenascin-X deficiencyUncertain significance
(Feb 15, 2022)
criteria provided, single submitter
15.
GRCh37:
Chr6:32017140
GRCh38:
Chr6:32049363
TNXBG3220R, G3222RCardiovascular phenotype, Ehlers-Danlos syndrome due to tenascin-X deficiencyConflicting interpretations of pathogenicity
(Nov 7, 2022)
criteria provided, conflicting interpretations
16.
GRCh37:
Chr6:32056820
GRCh38:
Chr6:32089043
TNXBD841NEhlers-Danlos syndrome due to tenascin-X deficiencyUncertain significance
(Oct 29, 2021)
criteria provided, single submitter
17.
GRCh37:
Chr6:32039874
GRCh38:
Chr6:32072097
TNXBR1628Qnot provided, Ehlers-Danlos syndrome due to tenascin-X deficiency, Cardiovascular phenotype
Uncertain significance
(May 23, 2023)
criteria provided, multiple submitters, no conflicts
18.
GRCh37:
Chr6:32010470
GRCh38:
Chr6:32042693
LOC106780803, TNXBnot provided, Vesicoureteral reflux 8, Ehlers-Danlos syndrome due to tenascin-X deficiency
Likely benign
(Apr 1, 2022)
criteria provided, multiple submitters, no conflicts
19.
GRCh37:
Chr6:32056638
GRCh38:
Chr6:32088861
TNXBCardiovascular phenotype, Vesicoureteral reflux 8, Ehlers-Danlos syndrome due to tenascin-X deficiency
Uncertain significance
(Dec 21, 2021)
criteria provided, multiple submitters, no conflicts
20.
GRCh37:
Chr6:32062915
GRCh38:
Chr6:32095138
TNXBR766WVesicoureteral reflux 8, Ehlers-Danlos syndrome due to tenascin-X deficiencyUncertain significance
(Feb 4, 2022)
criteria provided, single submitter
21.
GRCh37:
Chr6:32025841
GRCh38:
Chr6:32058064
TNXBV2607IVesicoureteral reflux 8, Ehlers-Danlos syndrome due to tenascin-X deficiencyUncertain significance
(Feb 8, 2022)
criteria provided, single submitter
22.
GRCh37:
Chr6:32036778
GRCh38:
Chr6:32069001
TNXBF1908YCardiovascular phenotype, Vesicoureteral reflux 8, Ehlers-Danlos syndrome due to tenascin-X deficiency
Uncertain significance
(Jun 19, 2022)
criteria provided, multiple submitters, no conflicts
23.
GRCh37:
Chr6:32036590
GRCh38:
Chr6:32068813
TNXBVesicoureteral reflux 8, Ehlers-Danlos syndrome due to tenascin-X deficiencyUncertain significance
(Mar 30, 2021)
criteria provided, single submitter
24.
GRCh37:
Chr6:32029328
GRCh38:
Chr6:32061551
TNXBK2446NEhlers-Danlos syndrome due to tenascin-X deficiencynot providedno assertion provided
25.
GRCh37:
Chr6:32063891
GRCh38:
Chr6:32096114
TNXBY580CCardiovascular phenotype, Ehlers-Danlos syndrome due to tenascin-X deficiency, Vesicoureteral reflux 8
Uncertain significance
(Oct 11, 2021)
criteria provided, multiple submitters, no conflicts
26.
GRCh37:
Chr6:32009655-32009656
GRCh38:
Chr6:32041878-32041879
LOC106780803, TNXBN4174fs, N4176fs, N605fsEhlers-Danlos syndrome due to tenascin-X deficiencyUncertain significance
(Dec 23, 2021)
criteria provided, single submitter
27.
GRCh37:
Chr6:32032606
GRCh38:
Chr6:32064829
TNXBG2278VCardiovascular phenotype, Vesicoureteral reflux 8, Ehlers-Danlos syndrome due to tenascin-X deficiency,
not provided
Uncertain significance
(Apr 1, 2022)
criteria provided, multiple submitters, no conflicts
28.
GRCh37:
Chr6:32021483
GRCh38:
Chr6:32053706
TNXBE2825KEhlers-Danlos syndrome due to tenascin-X deficiency, Vesicoureteral reflux 8Likely pathogenic
(Feb 22, 2021)
criteria provided, multiple submitters, no conflicts
29.
GRCh37:
Chr6:32065767
GRCh38:
Chr6:32097990
TNXBQ70RCardiovascular phenotype, Ehlers-Danlos syndrome, Vesicoureteral reflux 8,
Ehlers-Danlos syndrome due to tenascin-X deficiency, not provided
Uncertain significance
(Dec 2, 2022)
criteria provided, multiple submitters, no conflicts
30.
GRCh37:
Chr6:32065134
GRCh38:
Chr6:32097357
TNXBT166Pnot providedUncertain significance
(Jan 20, 2022)
criteria provided, single submitter
31.
GRCh37:
Chr6:32025877
GRCh38:
Chr6:32058100
TNXBE2595KVesicoureteral reflux 8, Ehlers-Danlos syndrome due to tenascin-X deficiency, Cardiovascular phenotype,
not provided
Uncertain significance
(Nov 15, 2021)
criteria provided, multiple submitters, no conflicts
32.
GRCh37:
Chr6:32029933
GRCh38:
Chr6:32062156
TNXBCardiovascular phenotype, Ehlers-Danlos syndrome due to tenascin-X deficiencyConflicting interpretations of pathogenicity
(Apr 1, 2020)
criteria provided, conflicting interpretations
33.
GRCh37:
Chr6:32029207
GRCh38:
Chr6:32061430
TNXBR2487Cnot provided, Cardiovascular phenotype, Ehlers-Danlos syndrome due to tenascin-X deficiency
Uncertain significance
(Dec 17, 2022)
criteria provided, multiple submitters, no conflicts
34.
GRCh37:
Chr6:32064182-32064367
GRCh38:
Chr6:32096405-32096590
TNXBCardiovascular phenotype, not providedUncertain significance
(Dec 8, 2021)
criteria provided, multiple submitters, no conflicts
35.
GRCh37:
Chr6:32023706
GRCh38:
Chr6:32055929
TNXBG2797WEhlers-Danlos syndrome due to tenascin-X deficiencyUncertain significance
(Feb 22, 2021)
criteria provided, single submitter
36.
GRCh37:
Chr6:32041621
GRCh38:
Chr6:32073844
TNXBT1495ICardiovascular phenotype, Ehlers-Danlos syndrome, Ehlers-Danlos syndrome due to tenascin-X deficiency,
Vesicoureteral reflux 8, not provided
Benign/Likely benign
(Jul 22, 2021)
criteria provided, multiple submitters, no conflicts
37.
GRCh37:
Chr6:32025910
GRCh38:
Chr6:32058133
TNXBR2584CVesicoureteral reflux 8, Ehlers-Danlos syndrome due to tenascin-X deficiency, Cardiovascular phenotype,
not provided, Ehlers-Danlos syndrome
Conflicting interpretations of pathogenicity
(Mar 30, 2023)
criteria provided, conflicting interpretations
38.
GRCh37:
Chr6:32024560
GRCh38:
Chr6:32056783
TNXBT2649MCardiovascular phenotype, not provided, Ehlers-Danlos syndrome due to tenascin-X deficiency,
Vesicoureteral reflux 8
Uncertain significance
(Jul 25, 2022)
criteria provided, multiple submitters, no conflicts
39.
GRCh37:
Chr6:32056840-32056842
GRCh38:
Chr6:32089063-32089065
TNXBEhlers-Danlos syndrome due to tenascin-X deficiency, Vesicoureteral reflux 8, not provided
Benign
(Nov 29, 2021)
criteria provided, multiple submitters, no conflicts
40.
GRCh37:
Chr6:32008963
GRCh38:
Chr6:32041186
CYP21A2, TNXBEhlers-Danlos syndrome due to tenascin-X deficiency, Vesicoureteral reflux 8, not provided
Benign
(Aug 9, 2021)
criteria provided, multiple submitters, no conflicts
41.
GRCh37:
Chr6:32037475
GRCh38:
Chr6:32069698
TNXBD1814ECardiovascular phenotype, Ehlers-Danlos syndrome, not provided,
Ehlers-Danlos syndrome due to tenascin-X deficiency, Vesicoureteral reflux 8
Benign/Likely benign
(Aug 27, 2021)
criteria provided, multiple submitters, no conflicts
42.
GRCh37:
Chr6:32035679
GRCh38:
Chr6:32067902
TNXBCardiovascular phenotype, Ehlers-Danlos syndrome, not provided,
Ehlers-Danlos syndrome due to tenascin-X deficiency, Vesicoureteral reflux 8
Conflicting interpretations of pathogenicity
(Mar 8, 2022)
criteria provided, conflicting interpretations
43.
GRCh37:
Chr6:32036176
GRCh38:
Chr6:32068399
TNXBG2071RCardiovascular phenotype, Ehlers-Danlos syndrome, not provided,
Ehlers-Danlos syndrome due to tenascin-X deficiency, Vesicoureteral reflux 8
Uncertain significance
(Jul 6, 2023)
criteria provided, multiple submitters, no conflicts
44.
GRCh37:
Chr6:32049426
GRCh38:
Chr6:32081649
TNXBP1254RCardiovascular phenotype, Ehlers-Danlos syndrome, not provided,
Ehlers-Danlos syndrome due to tenascin-X deficiency, Vesicoureteral reflux 8
Uncertain significance
(Nov 11, 2022)
criteria provided, multiple submitters, no conflicts
45.
GRCh37:
Chr6:32065863
GRCh38:
Chr6:32098086
TNXBR38QEhlers-Danlos syndrome, Ehlers-Danlos syndrome due to tenascin-X deficiency, Vesicoureteral reflux 8,
Cardiovascular phenotype, not provided
Benign/Likely benign
(Sep 13, 2023)
criteria provided, multiple submitters, no conflicts
46.
GRCh37:
Chr6:32052409
GRCh38:
Chr6:32084632
TNXBD1076NCardiovascular phenotype, Vesicoureteral reflux 8, Ehlers-Danlos syndrome,
not provided, Ehlers-Danlos syndrome due to tenascin-X deficiency, Vesicoureteral reflux 8
Conflicting interpretations of pathogenicity
(Jul 14, 2023)
criteria provided, conflicting interpretations
47.
GRCh37:
Chr6:32017346
GRCh38:
Chr6:32049569
TNXBP3151R, P3153RCardiovascular phenotype, Ehlers-Danlos syndrome due to tenascin-X deficiency, Vesicoureteral reflux 8,
not provided
Uncertain significance
(Nov 25, 2022)
criteria provided, multiple submitters, no conflicts
48.
GRCh37:
Chr6:32053892
GRCh38:
Chr6:32086115
TNXBS928YCardiovascular phenotype, Vesicoureteral reflux 8, Ehlers-Danlos syndrome,
Ehlers-Danlos syndrome due to tenascin-X deficiency, Vesicoureteral reflux 8, not provided
Uncertain significance
(Jun 13, 2023)
criteria provided, multiple submitters, no conflicts
49.
GRCh37:
Chr6:32021489
GRCh38:
Chr6:32053712
TNXBEhlers-Danlos syndrome, not provided, Vesicoureteral reflux 8,
Ehlers-Danlos syndrome due to tenascin-X deficiency
Conflicting interpretations of pathogenicity
(Oct 23, 2021)
criteria provided, conflicting interpretations
50.
GRCh37:
Chr6:32037426
GRCh38:
Chr6:32069649
TNXBV1831Mnot provided, Cardiovascular phenotypeUncertain significance
(Feb 16, 2023)
criteria provided, multiple submitters, no conflicts
51.
GRCh37:
Chr6:32057130
GRCh38:
Chr6:32089353
TNXBVesicoureteral reflux 8, Ehlers-Danlos syndrome due to tenascin-X deficiency, Cardiovascular phenotype,
not provided
Likely benign
(Jan 28, 2022)
criteria provided, multiple submitters, no conflicts
52.
GRCh37:
Chr6:32010227
GRCh38:
Chr6:32042450
LOC106780803, TNXBVesicoureteral reflux 8, Ehlers-Danlos syndrome due to tenascin-X deficiency, not provided
Likely benign
(Sep 1, 2021)
criteria provided, multiple submitters, no conflicts
53.
GRCh37:
Chr6:32030051
GRCh38:
Chr6:32062274
TNXBG2351Rnot provided, Vesicoureteral reflux 8, Ehlers-Danlos syndrome due to tenascin-X deficiency,
Cardiovascular phenotype
Benign/Likely benign
(May 11, 2022)
criteria provided, multiple submitters, no conflicts
54.
GRCh37:
Chr6:32049177
GRCh38:
Chr6:32081400
TNXBR1337HEhlers-Danlos syndrome, not provided, Vesicoureteral reflux 8,
Ehlers-Danlos syndrome due to tenascin-X deficiency, Cardiovascular phenotype
Uncertain significance
(Jun 1, 2023)
criteria provided, multiple submitters, no conflicts
55.
GRCh37:
Chr6:32064134
GRCh38:
Chr6:32096357
TNXBG499DVesicoureteral reflux 8, Ehlers-Danlos syndrome due to tenascin-X deficiency, not provided,
Cardiovascular phenotype
Uncertain significance
(Jul 26, 2022)
criteria provided, multiple submitters, no conflicts
56.
GRCh37:
Chr6:32016423
GRCh38:
Chr6:32048646
TNXBVesicoureteral reflux 8, Ehlers-Danlos syndrome due to tenascin-X deficiency, Ehlers-Danlos syndrome,
Cardiovascular phenotype, not provided
Benign/Likely benign
(Mar 17, 2022)
criteria provided, multiple submitters, no conflicts
57.
GRCh37:
Chr6:32017224
GRCh38:
Chr6:32049447
TNXBD3192N, D3194NVesicoureteral reflux 8, Ehlers-Danlos syndrome due to tenascin-X deficiency, Cardiovascular phenotype,
not provided
Uncertain significance
(Aug 8, 2023)
criteria provided, multiple submitters, no conflicts
58.
GRCh37:
Chr6:32065890
GRCh38:
Chr6:32098113
TNXBR29QVesicoureteral reflux 8, Ehlers-Danlos syndrome due to tenascin-X deficiency, Ehlers-Danlos syndrome,
not provided, Cardiovascular phenotype
Benign/Likely benign
(Mar 17, 2022)
criteria provided, multiple submitters, no conflicts
59.
GRCh37:
Chr6:32064150
GRCh38:
Chr6:32096373
TNXBT494SCardiovascular phenotype, not providedUncertain significance
(May 15, 2023)
criteria provided, multiple submitters, no conflicts
60.
GRCh37:
Chr6:32025858
GRCh38:
Chr6:32058081
TNXBP2601LVesicoureteral reflux 8, Ehlers-Danlos syndrome due to tenascin-X deficiency, not provided,
Cardiovascular phenotype
Conflicting interpretations of pathogenicity
(May 6, 2022)
criteria provided, conflicting interpretations
61.
GRCh37:
Chr6:32032634
GRCh38:
Chr6:32064857
TNXBQ2269*not providedLikely pathogenic
(Oct 14, 2022)
criteria provided, single submitter
62.
GRCh37:
Chr6:32009589
GRCh38:
Chr6:32041812
LOC106780803, TNXBA4196T, A4198T, A627Tnot provided, Vesicoureteral reflux 8, Ehlers-Danlos syndrome due to tenascin-X deficiency
Likely benign
(Apr 1, 2022)
criteria provided, multiple submitters, no conflicts
63.
GRCh37:
Chr6:32063547
GRCh38:
Chr6:32095770
TNXBR695WVesicoureteral reflux 8, Ehlers-Danlos syndrome due to tenascin-X deficiency, Inborn genetic diseases,
not provided
Uncertain significance
(Sep 13, 2022)
criteria provided, multiple submitters, no conflicts
64.
GRCh37:
Chr6:32029253
GRCh38:
Chr6:32061476
TNXBVesicoureteral reflux 8, Ehlers-Danlos syndrome due to tenascin-X deficiency, Cardiovascular phenotype,
not provided
Benign/Likely benign
(Dec 30, 2021)
criteria provided, multiple submitters, no conflicts
65.
GRCh37:
Chr6:32025956
GRCh38:
Chr6:32058179
TNXBVesicoureteral reflux 8, Ehlers-Danlos syndrome due to tenascin-X deficiency, not provided,
Cardiovascular phenotype
Benign/Likely benign
(Sep 1, 2021)
criteria provided, multiple submitters, no conflicts
66.
GRCh37:
Chr6:32021325
GRCh38:
Chr6:32053548
TNXBQ2875H, Q2877Hnot provided, Cardiovascular phenotype, Vesicoureteral reflux 8,
Ehlers-Danlos syndrome due to tenascin-X deficiency
Uncertain significance
(Aug 25, 2021)
criteria provided, multiple submitters, no conflicts
67.
GRCh37:
Chr6:32010461
GRCh38:
Chr6:32042684
LOC106780803, TNXBVesicoureteral reflux 8, Ehlers-Danlos syndrome due to tenascin-X deficiency, not provided
Likely benign
(May 13, 2022)
criteria provided, multiple submitters, no conflicts
68.
GRCh37:
Chr6:32036363
GRCh38:
Chr6:32068586
TNXBCardiovascular phenotype, not provided, Vesicoureteral reflux 8,
Ehlers-Danlos syndrome due to tenascin-X deficiency
Benign/Likely benign
(Sep 1, 2021)
criteria provided, multiple submitters, no conflicts
69.
GRCh37:
Chr6:32053864
GRCh38:
Chr6:32086087
TNXBVesicoureteral reflux 8, Ehlers-Danlos syndrome due to tenascin-X deficiency, Ehlers-Danlos syndrome,
Cardiovascular phenotype, not provided
Conflicting interpretations of pathogenicity
(Jun 27, 2022)
criteria provided, conflicting interpretations
70.
GRCh37:
Chr6:32053641
GRCh38:
Chr6:32085864
TNXBV1012IEhlers-Danlos syndrome due to tenascin-X deficiency, Vesicoureteral reflux 8, not provided,
Cardiovascular phenotype, Ehlers-Danlos syndrome
Conflicting interpretations of pathogenicity
(Feb 23, 2023)
criteria provided, conflicting interpretations
71.
GRCh37:
Chr6:32056594
GRCh38:
Chr6:32088817
TNXBV916AEhlers-Danlos syndrome due to tenascin-X deficiencyUncertain significance
(Dec 13, 2018)
criteria provided, single submitter
72.
GRCh37:
Chr6:32020490
GRCh38:
Chr6:32052713
TNXBH3022Q, H3024QEhlers-Danlos syndrome due to tenascin-X deficiencyUncertain significance
(Aug 1, 2018)
criteria provided, single submitter
73.
GRCh37:
Chr6:32064842
GRCh38:
Chr6:32097065
TNXBR263Hnot provided, Cardiovascular phenotype, Ehlers-Danlos syndrome due to tenascin-X deficiency
Uncertain significance
(Feb 10, 2022)
criteria provided, multiple submitters, no conflicts
74.
GRCh37:
Chr6:32036632
GRCh38:
Chr6:32068855
TNXBH1957YEhlers-Danlos syndrome due to tenascin-X deficiencyUncertain significance
(Jun 29, 2018)
criteria provided, single submitter
75.
GRCh37:
Chr6:32039896
GRCh38:
Chr6:32072119
TNXBV1621Mnot provided, Cardiovascular phenotype, Ehlers-Danlos syndrome due to tenascin-X deficiency
Uncertain significance
(Apr 25, 2023)
criteria provided, multiple submitters, no conflicts
76.
GRCh37:
Chr6:32037555
GRCh38:
Chr6:32069778
TNXBT1788fsEhlers-Danlos syndrome due to tenascin-X deficiencyPathogeniccriteria provided, single submitter
77.
GRCh37:
Chr6:32065068
GRCh38:
Chr6:32097291
TNXBP188SEhlers-Danlos syndrome due to tenascin-X deficiency, Vesicoureteral reflux 8, Cardiovascular phenotype
Uncertain significance
(Oct 11, 2022)
criteria provided, multiple submitters, no conflicts
78.
GRCh37:
Chr6:32065689
GRCh38:
Chr6:32097912
TNXBL96HEhlers-Danlos syndrome due to tenascin-X deficiency, Vesicoureteral reflux 8Uncertain significance
(Mar 30, 2021)
criteria provided, single submitter
79.
GRCh37:
Chr6:32035662
GRCh38:
Chr6:32067885
TNXBS2107CEhlers-Danlos syndrome due to tenascin-X deficiencyUncertain significance
(Feb 4, 2019)
criteria provided, single submitter
80.
GRCh37:
Chr6:32026114
GRCh38:
Chr6:32058337
TNXBA2516TCardiovascular phenotype, Ehlers-Danlos syndrome due to tenascin-X deficiencyUncertain significance
(Apr 3, 2023)
criteria provided, multiple submitters, no conflicts
81.
GRCh37:
Chr6:32012194
GRCh38:
Chr6:32044417
LOC106780803, TNXBD172N, D3741N, D3743NEhlers-Danlos syndrome, Ehlers-Danlos syndrome due to tenascin-X deficiencyUncertain significance
(Aug 28, 2020)
criteria provided, multiple submitters, no conflicts
82.
GRCh37:
Chr6:32037429
GRCh38:
Chr6:32069652
TNXBS1830RCardiovascular phenotype, not provided, Ehlers-Danlos syndrome due to tenascin-X deficiency,
Inborn genetic diseases, Ehlers-Danlos syndrome
Conflicting interpretations of pathogenicity
(Mar 15, 2022)
criteria provided, conflicting interpretations
83.
GRCh37:
Chr6:32050061
GRCh38:
Chr6:32082284
TNXBG1163EEhlers-Danlos syndrome, Vesicoureteral reflux 8, not provided,
Cardiovascular phenotype, Ehlers-Danlos syndrome due to tenascin-X deficiency
Uncertain significance
(May 26, 2023)
criteria provided, multiple submitters, no conflicts
84.
GRCh37:
Chr6:32023663
GRCh38:
Chr6:32055886
TNXBR2811QEhlers-Danlos syndrome, not provided, Cardiovascular phenotype,
Ehlers-Danlos syndrome due to tenascin-X deficiency
Conflicting interpretations of pathogenicity
(Jul 13, 2023)
criteria provided, conflicting interpretations
85.
GRCh37:
Chr6:32018002
GRCh38:
Chr6:32050225
TNXBA3069V, A3071Vnot provided, Vesicoureteral reflux 8, Ehlers-Danlos syndrome due to tenascin-X deficiency,
Cardiovascular phenotype
Uncertain significance
(Nov 19, 2021)
criteria provided, multiple submitters, no conflicts
86.
GRCh37:
Chr6:32021195
GRCh38:
Chr6:32053418
TNXBV2919M, V2921MCardiovascular phenotype, Vesicoureteral reflux 8, not provided,
Vesicoureteral reflux 8, Ehlers-Danlos syndrome due to tenascin-X deficiency
Conflicting interpretations of pathogenicity
(Apr 30, 2023)
criteria provided, conflicting interpretations
87.
GRCh37:
Chr6:32046976
GRCh38:
Chr6:32079199
TNXBCardiovascular phenotype, not provided, Vesicoureteral reflux 8,
Ehlers-Danlos syndrome due to tenascin-X deficiency
Likely benign
(Jan 3, 2022)
criteria provided, multiple submitters, no conflicts
88.
GRCh37:
Chr6:32032790
GRCh38:
Chr6:32065013
TNXBP2217TCardiovascular phenotype, Ehlers-Danlos syndrome, not provided,
Ehlers-Danlos syndrome due to tenascin-X deficiency
Conflicting interpretations of pathogenicity
(May 4, 2023)
criteria provided, conflicting interpretations
89.
GRCh37:
Chr6:32053673
GRCh38:
Chr6:32085896
TNXBP1001LEhlers-Danlos syndrome due to tenascin-X deficiency, not providedUncertain significance
(Oct 13, 2022)
criteria provided, multiple submitters, no conflicts
90.
GRCh37:
Chr6:32012921
GRCh38:
Chr6:32045144
LOC106780803, TNXBP26S, P3595S, P3597SEhlers-Danlos syndrome due to tenascin-X deficiencyUncertain significance
(Apr 8, 2019)
criteria provided, single submitter
91.
GRCh37:
Chr6:32029976
GRCh38:
Chr6:32062199
TNXBG2376CEhlers-Danlos syndrome due to tenascin-X deficiencyUncertain significance
(Jan 1, 2019)
criteria provided, single submitter
92.
GRCh37:
Chr6:32063460
GRCh38:
Chr6:32095683
TNXBR724CCardiovascular phenotype, Ehlers-Danlos syndrome due to tenascin-X deficiency, Ehlers-Danlos syndrome due to tenascin-X deficiency,
Vesicoureteral reflux 8, Ehlers-Danlos syndrome, not provided
Conflicting interpretations of pathogenicity
(May 1, 2023)
criteria provided, conflicting interpretations
93.
GRCh37:
Chr6:32064769
GRCh38:
Chr6:32096992
TNXBCardiovascular phenotype, Ehlers-Danlos syndrome due to tenascin-X deficiency, Vesicoureteral reflux 8
Conflicting interpretations of pathogenicity
(Apr 7, 2023)
criteria provided, conflicting interpretations
94.
GRCh37:
Chr6:32052423
GRCh38:
Chr6:32084646
TNXBT1071RCardiovascular phenotype, Ehlers-Danlos syndrome due to tenascin-X deficiency, Vesicoureteral reflux 8
Uncertain significance
(Nov 15, 2022)
criteria provided, multiple submitters, no conflicts
95.
GRCh37:
Chr6:32037501
GRCh38:
Chr6:32069724
TNXBF1806Lnot provided, Ehlers-Danlos syndrome due to tenascin-X deficiency, Vesicoureteral reflux 8
Uncertain significance
(Apr 24, 2023)
criteria provided, multiple submitters, no conflicts
96.
GRCh37:
Chr6:32036210
GRCh38:
Chr6:32068433
TNXBH2059QCardiovascular phenotype, not provided, Ehlers-Danlos syndrome due to tenascin-X deficiency,
Vesicoureteral reflux 8
Uncertain significance
(Jul 18, 2023)
criteria provided, multiple submitters, no conflicts
97.
GRCh37:
Chr6:32013077
GRCh38:
Chr6:32045300
LOC106780803, TNXBE3543K, E3545KEhlers-Danlos syndrome due to tenascin-X deficiency, Vesicoureteral reflux 8Uncertain significance
(Mar 30, 2021)
criteria provided, single submitter
98.
GRCh37:
Chr6:32023909
GRCh38:
Chr6:32056132
TNXBE2729GCardiovascular phenotype, not provided, Ehlers-Danlos syndrome due to tenascin-X deficiency,
Vesicoureteral reflux 8
Uncertain significance
(Mar 24, 2023)
criteria provided, multiple submitters, no conflicts
99.
GRCh37:
Chr6:32024650
GRCh38:
Chr6:32056873
TNXBP2619LCardiovascular phenotype, Inborn genetic diseases, Ehlers-Danlos syndrome,
not provided, Ehlers-Danlos syndrome due to tenascin-X deficiency
Conflicting interpretations of pathogenicity
(Jun 20, 2023)
criteria provided, conflicting interpretations
100.
GRCh37:
Chr6:32029249
GRCh38:
Chr6:32061472
TNXBR2473CCardiovascular phenotype, not provided, Ehlers-Danlos syndrome due to tenascin-X deficiency,
Vesicoureteral reflux 8
Benign/Likely benign
(Jul 19, 2021)
criteria provided, multiple submitters, no conflicts
Format
Items per page
Sort by
Choose Destination